title: Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study.
authors.forename: E
authors.initials: E
authors.lastname: Collantes-Estévez
authors.forename: M C
authors.initials: MC
authors.lastname: Muñoz-Villanueva
authors.forename: J D
authors.initials: JD
authors.lastname: Cañete-Crespillo
authors.forename: R
authors.initials: R
authors.lastname: Sanmartí-Sala
authors.forename: J
authors.initials: J
authors.lastname: Gratacós-Masmitjá
authors.forename: P
authors.initials: P
authors.lastname: Zarco-Montejo
authors.forename: J C
authors.initials: JC
authors.lastname: Torre-Alonso
authors.forename: C
authors.initials: C
authors.lastname: González-Fernández
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D011446:Prospective Studies; D025242:Spondylarthropathies / Q000188:drug therapy*; D013904:Thoracic Vertebrae
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab